Introduction
============

Lung cancer is a type of malignant tumor that causes considerable mortality and morbidity worldwide ([@b1-ol-0-0-10659]). Out of all lung cancer cases, \>85% are non-small cell lung cancer (NSCLC) ([@b2-ol-0-0-10659]). Surgical intervention, chemotherapy and radiation therapy are the traditional therapies for early-stage lung cancer; however, all these treatments are accompanied by undesirable adverse reactions. In recent years, molecular targeted therapies, which specifically target carcinoma cells, and reportedly have minimal adverse effects compared with conventional treatments, have become a research focus ([@b3-ol-0-0-10659]). Currently, a large amount of molecular therapies targeting diverse receptor tyrosine kinases (RTKs), which have been demonstrated to be frequently mutated and to promote tumorigenesis by regulating cell proliferation and survival, are widely used in patients with NSCLC ([@b4-ol-0-0-10659]). Numerous types of RTKs, including epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-Met), ALK receptor tyrosine kinase (ALK) and BRAF, which have been reported to be frequently mutated in patients with NSCLC, have been used as targets in clinical therapy ([@b5-ol-0-0-10659]--[@b10-ol-0-0-10659]). However, despite all these therapies, the majority of patients with NSCLC still exhibit a poor 5-year survival rate of 15.9% ([@b11-ol-0-0-10659]). Therefore, there is an urgent need to identify biomarkers with better prognostic and diagnostic potential.

The cleavage polyadenylation specificity factor (CPSF) complex is a core component of 3′-end processing and is involved in regulating mRNA maturation and alternative splicing, as well as internal introns, by modulating the cleavage and polyadenylation of mRNAs ([@b12-ol-0-0-10659]). The multi-subunit CPSF complex is composed of CPSF1 (also known as CPSF160), CPSF2 (also known as CPSF100), CPSF3 (the cleavage endonuclease, also known as CPSF73), CPSF4 (also known as CPSF30), factor interacting with poly(A) polymerase α and CPSF1 (FIP1L1; also known as FIP1) and WD repeat domain 33 ([@b12-ol-0-0-10659]). There are several studies regarding the function of the CPSF complex in cancer, particularly in lung cancer; however, CPSF1 promotes cell proliferation in human ovarian cancer ([@b13-ol-0-0-10659]). Decreased CPSF2 expression promotes invasion and an increased cancer stem cell population, and CPSF2 may be a novel prognostic marker for papillary thyroid carcinoma ([@b14-ol-0-0-10659],[@b15-ol-0-0-10659]). Suppression of CPSF4 inhibits the proliferation of lung adenocarcinoma (LUAD) cells and is associated with overall survival (OS) ([@b16-ol-0-0-10659]--[@b19-ol-0-0-10659]). FIP1L1 is generated via gene fusion with platelet-derived growth factor receptor a, which is recognized as an important diagnostic marker of hematological malignancies, including chronic eosinophilic leukemia, hypereosinophilic syndrome and systemic mastocytosis, and occasionally atypical chronic myelogenous leukemia ([@b20-ol-0-0-10659]). Therefore, it was hypothesized that potential diagnostic and prognostic biomarkers could exist within the CPSF complex.

The Cancer Genome Atlas (TCGA; <http://portal.gdc.cancer.gov>) is an open-access database that is widely used globally and provides a reliable tool for the analysis of numerous types of useful clinicopathological data. In addition, TCGA data is overseen by the National Cancer Institute\'s Center for Cancer Genomics ([@b21-ol-0-0-10659]). Genetic and clinicopathological data of \>1,000 patients with primary LUAD and lung squamous cell carcinoma (LUSC) are recorded in the TCGA Lung Cancer Cohort ([@b22-ol-0-0-10659]).

In the present study, promising biomarkers for NSCLC were identified via bioinformatics data mining. The results of the present study demonstrated that CPSF3 of the CPSF complex was overexpressed in NSCLC, and its overexpression was associated with OS and recurrence-free survival (RFS) of patients with LUAD. CPSF3 may also serve as a diagnostic biomarker for LUAD and LUSC. Additionally, CPSF3 may promote the proliferation and lymph node metastasis of LUAD. The mechanism of CPSF3 overexpression may be connected to its DNA copy number variants and DNA hypermethylation.

Materials and methods
=====================

### TCGA Lung Cancer Cohort

TCGA Lung Cancer Cohort data, (<http://tcga.cancer.gov/dataportal>; accessed June 2016), which include the LUAD cohort, comprising 706 primary LUAD tissues and normal lung tissues, and the LUSC cohort, comprising 554 primary LUSC tissues and normal lung tissues, were downloaded from the University of California Santa Cruz Xena Browser (<https://xenabrowser.net>). Excel 2016 (Microsoft Corporation) was used for further data processing. From the cohorts, 520 primary LUAD cases and 506 primary LUSC cases with existing RNA-seq and intact clinical parameters were selected for further analysis. In addition, DNA methylation data ('Illumina 450k methylation') and CNA data ('gene-level GISTIC2-processed') were downloaded from this database to detect the possible mechanisms of abnormal expression of CPSF3 in LUAD.

### Cancer cell line encyclopedia (CCLE)

CCLE (<https://portals.broadinstitute.org/ccle/about>) is a database containing genomic data, including copy number, mRNA expression, reverse-phase protein microarray and reduced representation bisulfite sequencing, from \>1,100 cell lines. LUAD cell line data (based on The Global Bioresource Center; <http://www.atcc.org>) were downloaded to examine the association between CPSF3 expression and its DNA methylation.

### Statistical analysis

GraphPad Prism version 5.0 (GraphPad Software, Inc.) or SPSS version 16.0 (SPSS, Inc.) were used for data analysis. Unless specifically mentioned, all values are presented as the mean ± SD. Two-group independent sample comparisons were performed using a Student\'s t-test (two-tailed) when the two groups had equal variances, while Welch\'s t-test was used for unequal variances. Multi-group samples statistics were analyzed via one-way ANOVA if the variances were equal; if not, Welch\'s ANOVA was performed. Bonferroni post hoc tests were performed for all ANOVAs. Samples from TCGA Lung Cancer Cohort were divided into two groups, according to median values. OS and RFS curves were plotted using the Kaplan-Meier method, and OS and RFS differences were assessed using the log-rank test. Receiver operating characteristic (ROC) curves were constructed using CPSF3 expression data, and the area under the curve (AUC) was estimated to investigate the feasibility of distinguishing LUAD from LUSC. Pearson correlation analysis was used to evaluate the correlations among CPSF3 mRNA expression and CPSF3 DNA methylation and DNA copy number variants (CNAs). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### CPSF complex is significantly elevated in NSCLC tissues compared with normal lung tissues (NTL)

Expression levels of CPSF complex components were individually assessed in the TCGA LUAD and LUSC cohorts. The results indicated that all CPSF complex components were significantly overexpressed in LUAD ([Fig. 1](#f1-ol-0-0-10659){ref-type="fig"}) and LUSC ([Fig. 2](#f2-ol-0-0-10659){ref-type="fig"}) tissues compared with NTL.

### CPSF3 is the only component associated with lung cancer OS and RFS in the CPSF complex

To identify potential prognostic biomarkers in the CPSF complex, the associations among the CPSF complex components and OS and RFS in the TCGA Lung Cancer Cohort were assessed. The results of the present study demonstrated that overexpression of CPSF3 and FIP1L1 in patients with LUAD was associated with decreased survival times compared with patients with low expression levels of CPSF3 and FIP1L1 ([Fig. 3](#f3-ol-0-0-10659){ref-type="fig"}). In patients with LUSC, no CPSF complex components were significantly associated with OS ([Fig. 4](#f4-ol-0-0-10659){ref-type="fig"}). Additionally, analysis of the association between the CPSF complex component proteins and RFS was investigated. Patients with LUAD with high CPSF2 and CPSF3 had shorter RFS than those in the low expression groups ([Fig. 5](#f5-ol-0-0-10659){ref-type="fig"}), whereas expression of the components had no effect on RFS of patients with LUSC ([Fig. 6](#f6-ol-0-0-10659){ref-type="fig"}). Taken together, CPSF3 was the only CSPF complex component that affected OS and RFS, and it may thus function as a promising prognostic biomarker for NSCLC. Therefore, CPSF3 was considered as a potential biomarker and focused on in further research.

### CPSF3 serves as a biomarker to distinguish between histological subtypes of NSCLC

To further test whether CPSF3 could serve as a biomarker to distinguish between LUAD and LUSC, CPSF3 expression status of patients with LUAD and LUSC in the TCGA Lung Cancer Cohort was compared. As shown in [Fig. 7A](#f7-ol-0-0-10659){ref-type="fig"}, the average expression level of CPSF3 among 502 patients with LUSC was higher than that of 512 patients with LUAD. ROC analysis further demonstrated that CPSF3 expression could be a single significant parameter to discriminate between LUAD and LUSC, with an AUC of 0.7014 ([Fig. 7B](#f7-ol-0-0-10659){ref-type="fig"}). To further explore the clinical implications of CPSF3, associations among CPSF3 expression and different molecular subtypes were investigated within different types of adenocarcinoma classified according to the genotypes of BRAF, erb-b2 receptor tyrosine kinase 4 (ERBB4), EGFR, echinoderm microtubule associated protein like 4, KRAS and serine/threonine kinase 11, and ALK translocation, in the TCGA-LUAD cohort. There was no difference in CPSF3 between the wild type and mutant samples categorized by any of the aforementioned genes of interest ([Fig. 7C-H](#f7-ol-0-0-10659){ref-type="fig"}). Overall, CPSF3 was shown to be a novel and efficient diagnostic biomarker for distinguishing between LUAD and LUSC in NSCLC.

### Association of CPSF3 expression with clinicopathological features in LUAD

To explore the role of high CPSF3 expression in LUAD progression, the association of clinicopathological features with CPSF3 expression was evaluated. The present study revealed that CPSF3 expression was associated with smoking history, tumor diameter, lymph node metastasis, TNM stage and radiation therapy, whereas there was no association with age, gender, distant metastasis and targeted molecular therapy in the TCGA-LUAD Cohort ([Table I](#tI-ol-0-0-10659){ref-type="table"}). Therefore, it was hypothesized that CPSF3 may promote proliferation and metastasis, and may be associated with radiation therapy.

### DNA methylation and DNA CNAs are correlated with CPSF3 expression in LUAD

DNA methylation is one of the most common factors associated with abnormal gene expression. By analyzing CPSF3 DNA methylation and RNA-seq data in the TCGA-LUAD Cohort, two CPSF3 DNA methylation CpG sites (cg12057242 and cg25739938) were identified to be differentially methylated in TCGA-LUAD tissues compared with normal lung tissues ([Table II](#tII-ol-0-0-10659){ref-type="table"}). The correlation between the two differentially expressed DNA CpG sites and RNA expression was assessed, demonstrating that cg25739938 exhibited a negative correlation with CPSF3 expression ([Fig. 8A and B](#f8-ol-0-0-10659){ref-type="fig"}). However, the same analysis conducted in 53 LUAD cell lines from CCLE indicated there was no correlation between CPSF3 expression and methylation ([Fig. 8C](#f8-ol-0-0-10659){ref-type="fig"}). DNA CNAs are another mechanism that leads to aberrant RNA expression. Therefore, the association between CPSF3 DNA CNAs and RNA expression was further analyzed. The results demonstrated that CPSF3 CNAs were positively correlated with CPSF3 mRNA expression in TCGA-LUAD samples ([Fig. 8D](#f8-ol-0-0-10659){ref-type="fig"}) and CCLE-LUAD cell lines ([Fig. 8E](#f8-ol-0-0-10659){ref-type="fig"}).

Discussion
==========

Previously, a number of promising potential biomarkers have been identified in a series of secondary analyses using TCGA data. For example, DNA methylation of SOX30 is correlated with myelodysplastic syndrome progression, and has been reported to act as a potential predictive and prognostic biomarker in acute myeloid leukemia ([@b23-ol-0-0-10659]). Higher FOS expression is associated with a better outcome in breast cancer datasets ([@b24-ol-0-0-10659]). Using public data from TCGA, a 22-gene signature that demonstrated the best predictive value for assessing the clinical benefit of postoperative chemoradiotherapy was established ([@b25-ol-0-0-10659]).

Compound gene analysis is a more effective way of elucidating novel biomarkers and assessing the interactions among individual genes. Targeting one of these genes may lead to a large feedback effect. CPSF complex components have been demonstrated to regulate the cleavage and polyadenylation of mRNAs during the mRNA maturation and alternative splicing processes ([@b12-ol-0-0-10659]). However, there are few reports regarding the role of CPSF4 in lung cancer ([@b16-ol-0-0-10659]--[@b19-ol-0-0-10659]), and, to the best of our knowledge, no reports on the other components. Therefore, TCGA data was utilized to elucidate potential prognostic and diagnostic biomarkers within the complex in the present study.

In the present study, CPSF complex components were first evaluated in terms of their expression levels in NSCLC using TCGA data, as biomarkers must be differentially expressed between cancer tissue and normal tissue. The results of the present study indicated that expression of all CPSF complex components was increased in NSCLC. A promising biomarker should affect prognosis and recurrence, and may therefore serve as a predictor. The associations of CPSF complex expression with OS and RFS were assessed, which demonstrated that CPSF3 was the only component that affected OS and RFS in LUAD. Additionally, there is only one previous report regarding the role of CPSF3 in cancer ([@b26-ol-0-0-10659]), and, to the best of our knowledge, no reports regarding the role of CPSF3 in lung cancer; therefore, the present study focused on CPSF3 for further research, as it appeared to be a potentially promising biomarker. Further ROC curve analysis demonstrated that CPSF3 may serve as a diagnostic biomarker for NSCLC to distinguish between LUAD and LUSC.

A previous study in prostate cancer demonstrated that knockdown of CPSF3 by a specific siRNA induces apoptosis ([@b26-ol-0-0-10659]), which verified that CPSF3 is associated with the proliferation of malignant carcinoma. To further assess the role of CPSF3 in LUAD, the association between clinicopathological features and CPSF3 was assessed. The present study revealed that CPSF3 expression was associated with smoking history, tumor diameter, lymph node metastasis, TNM stage and radiation therapy; thus, CPSF3 may affect LUAD proliferation and metastasis, consistent with the results of the aforementioned study in prostate cancer ([@b26-ol-0-0-10659]).

The mechanism of gene dysregulation in NSCLC is complex. Among all the mechanisms, genetic and epigenetic alterations, including DNA amplification, DNA methylation and somatic mutations, commonly lead to abnormal gene expression accompanied by anomalous cancer cell behavior. For instance, heteroclite sulfatase 2 methylation acts as a prognostic marker for lung cancer survival ([@b27-ol-0-0-10659]). ERBB2 amplification results in erlotinib resistance in EGFR-L858R mutated tyrosine kinase inhibitor-naïve LUAD ([@b28-ol-0-0-10659]). c-Met overexpression, HER-2 gene amplification and spectrin β non-erythrocytic 1-ALK gene fusion have been reported to coexist in LUAD, and this may become a novel biomarker for cancer that is refractory to crizotinib, chemotherapy and radiotherapy, and poor prognosis ([@b29-ol-0-0-10659]). Promoter methylation of cadherin 13 is strongly associated with LUAD and may function as a promising diagnostic biomarker for LUAD ([@b30-ol-0-0-10659]). Thus, the present study assessed whether DNA CNA and abnormal DNA methylation were the mechanism underlying the aberrant mRNA expression of CPSF3, similar to the aforementioned gene. In the present study, DNA methylation levels in TCGA LUAD tissues were compared with levels in normal lung tissues, which revealed two differentially expressed CpG sites. Further correlation analysis confirmed that cg25739938 was negatively correlated with CPSF3 expression, while cg12057242 in TCGA-LUAD Cohort patients and in LUAD cell lines has no correlation with CPSF3 expression. The aforementioned results suggested that the hypermethylation of cg25739938 may be the potential mechanism affecting CPSF3 mRNA expression in LUAD. Furthermore, the DNA amplification status of CPSF3 was detected. The results demonstrated that DNA CNAs were closely associated with increased CPSF3 expression, in TCGA LUAD Cohort patients and 53 LUAD cell lines. Overall, the dysregulation of CPSF3 may be caused by DNA methylation and DNA CNAs.

In summary, the present study is the first to elucidate the potential role of the CPSF complex, particularly CPSF3, in proliferation and migration in lung cancer. As the present study was conducted via bioinformatics analysis, experimental studies regarding the role of CPSF3 in LUAD will be performed in order to verify the results of the present study. In conclusion, aberrant CPSF3 expression may be regulated by DNA CNAs, and it may function as a promising prognostic and diagnostic biomarker for LUAD.
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![CPSF complex component mRNA expression in The Cancer Genome Atlas-LUAD tissues. CPSF complex components, including (A) CPSF1, (B) CPSF2, (C) CPSF3, (D) CPSF4, (E) FIP1L1 and (F) WDR33, were significantly overexpressed in LUAD tissues compared with in NTL. \*\*\*P\<0.0001. CPSF, cleavage polyadenylation specificity factor; NTL, normal lung tissue; LUAD, lung adenocarcinoma; FIP1L1, factor interacting with poly(A) polymerase α and CPSF1; WDR33, WD repeat domain 33.](ol-18-03-2835-g00){#f1-ol-0-0-10659}

![CPSF complex component mRNA expression in The Cancer Genome Atlas-LUSC tissues. All CPSF complex components, including (A) CPSF1, (B) CPSF2, (C) CPSF3, (D) CPSF4, (E) FIP1L1 and (F) WDR33, were significantly overexpressed in LUSC tissues compared with in NTL. \*\*\*P\<0.0001. CPSF, cleavage polyadenylation specificity factor; NTL, normal lung tissue; LUSC, lung squamous cell carcinoma; FIP1L1, factor interacting with poly(A) polymerase α and CPSF1; WDR33, WD repeat domain 33.](ol-18-03-2835-g01){#f2-ol-0-0-10659}

![Association between CPSF complex components and OS in TCGA-LUAD patients. Kaplan-Meier analysis of OS time of TCGA-LUAD Cohort patients. The patients were divided into high and low expression groups depending on the average expression level of CPSF complex (A) CPSF1 exhibited no association with OS in LUAD, (B) CPSF2 showed no association with OS in LUAD, (C) CPSF3 high expression showed reduced survival time compared with the patient with CPSF3 low expression in LUAD (D) CPSF4 exhibited no association with OS in LUAD, (E) FIP1L1 high expression showed reduced survival time compared with the patient with CPSF3 low expression in LUAD and (F) WDR33 showed no association with OS in LUAD.](ol-18-03-2835-g02){#f3-ol-0-0-10659}

![Association between CPSF complex components and OS in TCGA-LUSC patients. Kaplan-Meier analysis of OS time of TCGA-LUSC Cohort patients. The patients were divided into high and low expression groups depending on the average expression level of each gene. CPSF complex components, including (A) CPSF1, (B) CPSF2, (C) CPSF3, (D) CPSF4, (E) FIP1L1 and (F) WDR33, exhibited no connection with OS in LUSC. TCGA, The Cancer Genome Atlas; LUSC, lung squamous cell carcinoma; CPSF, cleavage polyadenylation specificity factor; OS, overall survival; FIP1L1, factor interacting with poly(A) polymerase α and CPSF1; WDR33, WD repeat domain 33.](ol-18-03-2835-g03){#f4-ol-0-0-10659}

![Association of CPSF complex components and RFS in TCGA-LUAD patients. Kaplan-Meier analysis of the RFS of TCGA-LUAD patients. The patients were stratified depending on the average expression level of (A) CPSF1, (B) CPSF2, (C) CPSF3, (D) CPSF4, (E) FIP1L1 and (F) WDR33. High expression levels of CPSF2 and CPSF3 were associated with the RFS of patients with LUAD. Overexpression of CPSF1, CPSF4, FIP1L1 and WDR33 had no influence on RFS. TCGA, The Cancer Genome Atlas; LUAD, lung adenocarcinoma; CPSF, cleavage polyadenylation specificity factor; RFS, recurrence-free survival; FIP1L1, factor interacting with poly(A) polymerase α and CPSF1; WDR33, WD repeat domain 33.](ol-18-03-2835-g04){#f5-ol-0-0-10659}

![Association between CPSF complex expression and RFS in TCGA-LUSC patients. Kaplan-Meier analysis of the RFS of TCGA-LUSC patients. The patients were stratified depending on the average expression level of each gene. CPSF complex members, including (A) CPSF1, (B) CPSF2, (C) CPSF3, (D) CPSF4, (E) FIP1L1 and (F) WDR33, exhibited no connection with RFS in LUSC. TCGA, The Cancer Genome Atlas; LUSC, lung squamous cell carcinoma; CPSF, cleavage polyadenylation specificity factor; RFS, recurrence-free survival; FIP1L1, factor interacting with poly(A) polymerase α and CPSF1; WDR33, WD repeat domain 33.](ol-18-03-2835-g05){#f6-ol-0-0-10659}

![CPSF3 functions as a biomarker to distinguish between the histological subtypes of non-small cell lung cancer. (A) Expression levels of CPSF3 were markedly higher in patients with LUSC than in patients with LUAD. (B) Receiver operating characteristic curve analysis revealed the potential use of CPSF3 expression to discriminate between patients with LUAD and LUSC in the TCGA Cohort. Comparison of the relative expression of CPSF3 between two groups of patients with LUAD in the TCGA Cohort, classified by molecular subtype based on (C) BRAF, (D) ERBB4, (E) ALK, (F) EGFR, (G) KRAS and (H) STK11 mutations, respectively. None of the mutations were identified to be associated with CPSF3 expression. \*\*\*P\<0.0001. TCGA, The Cancer Genome Atlas; CPSF3, cleavage polyadenylation specific factor 3; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; AUC, area under the curve; ERBB4, erb-b2 receptor tyrosine kinase 4; EML4, echinoderm microtubule associated protein like 4; ALK, ALK receptor tyrosine kinase; EGFR, epidermal growth factor receptor; STK11, serine/threonine kinase 11.](ol-18-03-2835-g06){#f7-ol-0-0-10659}

![Correlation of CPSF3 mRNA expression, and its DNA methylation and DNA copy number variants in TCGA-LUAD and in Cancer Cell Line Encyclopedia-LUAD cell lines. Correlation analysis revealed that (A) CPSF3 mRNA expression was not significantly correlated with DNA methylation at CpG site cg12057242, while (B) it was negatively correlated with its DNA methylation at CpG site cg25739938 in TCGA-LUAD. (C) Correlation analysis indicated that CPSF3 mRNA expression had no association with its DNA methylation in 53 LUAD cell lines. (D) Correlation analysis indicated that CPSF3 mRNA expression was positively correlated with its DNA copy number variants in TCGA-LUAD. (E) CPSF3 was positively correlated with its DNA copy number variants in LUAD cell lines. TCGA, The Cancer Genome Atlas; LUAD, lung adenocarcinoma; CPSF3, cleavage polyadenylation specific factor 3.](ol-18-03-2835-g07){#f8-ol-0-0-10659}

###### 

Association of CPSF3 with clinicopathological features in The Cancer Genome Atlas lung adenocarcinoma patients.

  Variable                N     CPSF3 (mean ± SE)                                            t-value   P-value
  ----------------------- ----- ------------------------------------------------------------ --------- ------------------------------------------------------
  Sex                                                                                                  
    Female                277   9.805±0.4380                                                 1.804     0.0717
    Male                  237   9.876±0.4555                                                           
  Age, years                                                                                           
    \<65                  220   9.871±0.4691                                                 1.693     0.0911
    ≥65                   275   9.876±0.4252                                                           
  Smoking history                                                                                      
    Smoked                75    9.700±0.4516                                                 2.937     0.0035^[a](#tfn1-ol-0-0-10659){ref-type="table-fn"}^
    Never smoked          425   9.766±0.3928                                                           
  Tumor diameter, cm                                                                                   
    ≤3                    169   9.876±0.4677                                                 2.638     0.0086^[a](#tfn1-ol-0-0-10659){ref-type="table-fn"}^
    \>3                   342   9.766±0.3928                                                           
  Lymph node metastasis                                                                                
    No                    330   9.805±0.4598                                                 2.763     0.0059^[a](#tfn1-ol-0-0-10659){ref-type="table-fn"}^
    Yes                   172   9.766±0.4188                                                           
  Distant metastasis                                                                                   
    M0                    346   9.853±0.4440                                                 1.611     0.1079
    M1                    25    9.921±0.4796                                                           
  TNM stage                                                                                            
    I                     425   9.792±0.4115                                                 4.178     0.0062^[a](#tfn1-ol-0-0-10659){ref-type="table-fn"}^
    II                    122   9.820±0.4917                                                           
    III                   84    9.961±0.4288^[b](#tfn2-ol-0-0-10659){ref-type="table-fn"}^             
    IV                    25    9.979±0.4837^[b](#tfn2-ol-0-0-10659){ref-type="table-fn"}^             
  Radiation therapy                                                                                    
    Yes                   60    9.812±0.4398                                                 2.742     0.0063^[a](#tfn1-ol-0-0-10659){ref-type="table-fn"}^
    No                    397   9.981±0.4847                                                           
  Molecular therapy                                                                                    
    No                    303   9.804±0.4477                                                 1.946     0.0523
    Yes                   152   9.891±0.4482                                                           

P\<0.01

P\<0.01 vs. stage I. Mean age, 65 years. TNM stage statistics were analyzed by one-way ANOVA and Bonferroni post hoc test. Other statistics were performed using a two-tailed Student\'s t-test. CPSF3, cleavage polyadenylation specific factor 3; TNM, tumor-node-metastasis.

###### 

CPSF3 DNA methylation CpG sites analysis in The Cancer Genome Atlas-LUAD.

  CpG site     Tissue   CpG methylation (mean ± SE)   t-value   P-value
  ------------ -------- ----------------------------- --------- ------------------------------------------------------
  cg23889771   NTL      0.0700±0.0196                 0.0107    0.9915
               LUAD     0.0700±0.0110                           
  cg24873957   NTL      0.0837±0.0137                 0.5146    0.6071
               LUAD     0.0825±0.0124                           
  cg20361001   NTL      0.0388±0.0083                 0.3778    0.7058
               LUAD     0.0040±0.0108                           
  cg20093808   NTL      0.0276±0.0067                 0.0731    0.9417
               LUAD     0.0274±0.0092                           
  cg07814910   NTL      0.0801±0.0187                 0.3878    0.6983
               LUAD     0.0792±0.0128                           
  cg20549545   NTL      0.0864±0.0178                 1.826     0.0685
               LUAD     0.0916±0.0139                           
  cg08937729   NTL      0.0948±0.0213                 0.1190    0.9054
               LUAD     0.0944±0.0173                           
  cg07179925   NTL      0.0288±0.0134                 1.171     0.2421
               LUAD     0.0268±0.0090                           
  cg00024812   NTL      0.0601±0.0152                 1.133     0.2578
               LUAD     0.0573±0.0133                           
  cg26306976   NTL      0.0795±0.0482                 0.6744    0.5004
               LUAD     0.7806±0.1175                           
  cg07974891   NTL      0.6744±0.0430                 0.2672    0.7894
               LUAD     0.6685±0.1237                           
  cg18666330   NTL      0.8918±0.0274                 1.260     0.2083
               LUAD     0.8856±0.0261                           
  cg12057242   NTL      0.5333±0.0448                 2.207     0.0278^[a](#tfn3-ol-0-0-10659){ref-type="table-fn"}^
               LUAD     0.5772±0.1117                           
  cg25739938   NTL      0.8485±0.8658                 2.137     0.0331^[a](#tfn3-ol-0-0-10659){ref-type="table-fn"}^
               LUAD     0.8658±0.0445                           
  cg18794882   NTL      0.8378±0.0475                 1.774     0.0767
               LUAD     0.8187±0.0595                           

P\<0.05. CPSF3, cleavage polyadenylation specific factor 3; LUAD, lung adenocarcinoma; NTL, normal lung tissue.

[^1]: Contributed equally
